Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Definition of a recommended Phase III dose and determination CTC version 3.0 grade 3-5 non-hematological toxicities of SU11248 in combination with standard induction and consolidation chemotherapy [ Time Frame: April 2011 ]
Secondary Outcome Measures :
Overall safety profile of SU11248 characterized by type, frequency, severity (graded using NCI CTCAE Version 3.0), timing and relatedness of adverse events (AEs) and laboratory [ Time Frame: April 2011 ]
Objective tumor response, as defined using the revised recommendations of the International Working Group for diagnosis, standardization of response criteria in Acute Myeloid Leukemia for AML [ Time Frame: April 2011 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
60 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with primary or secondary acute myeloid leukemia (any FAB type, except M3).
No prior systemic chemotherapy for AML except hydroxyurea. Cytoreductive therapy with hydroxyurea is recommended if WBC is > 50.000/µl, but should cease at least one day prior to starting study medication
Patient age equal or of greater than 60 years
Patients must have FLT3 mutated AML, either ITD or kinase domain mutations
ECOG Performance score 3 or less (Karnofsky Performance Score >40%).
Life expectancy more than four weeks.
Adequate hepatic and renal function, as defined by serum transaminases <2.5x ULN, bilirubin <1.5x ULN. Creatinine <1.5x ULN.
Patients must provide written informed consent to participate in the trial.
Normal heart function on cardiac ultrasound
Prothrombin time (PT) and partial thromboplastin time (PTT) <=1.5 x ULN
Serum albumin >=3.0 g/dl
Serum amylase and lipase <=1.0 x ULN
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
The presence of any of the following will exclude a subject from study enrollment:
Treatment with any investigational agent within four weeks.
Known HIV infection
Presence of any medical or psychiatric condition which may limit full compliance with the study, including but not limited to:
Presence of CNS leukaemia
Unresolved toxicity from previous anti-cancer therapy or incomplete recovery from surgery.
Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event.
Current treatment with therapeutic doses of anticoagulant (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy).
Pre existing thyroid abnormality of thyroid function that cannot be maintained in the normal range with medication.
Ongoing cardiac dysrhythmias of NCI CTCAE Grade >=2, atrial fibrillation of any Grade, or prolongation of the QTc interval to >450 msec for males or >470 msec for females.
Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.